Sumitomo Mitsui Trust Group Inc. Has $937.46 Million Holdings in AbbVie Inc. $ABBV

Key Points

• Sumitomo Mitsui Trust Group trimmed its AbbVie stake by 3.6% to 4,102,845 shares worth $937.46 million, making AbbVie its 24th-largest holding and about 0.23% of the company.
• AbbVie beat Q4 estimates with $2.71 EPS and revenue up ~10% year-over-year, but the company's lowered Q1 (2.56–2.60) and FY 2026 (13.96–14.16) EPS guidance is cited as the primary near-term negative catalyst.
• AbbVie declared a quarterly dividend of $1.73 (annualized $6.92) for a ~3.3% yield, though the payout ratio is very high at about 293%.

Sumitomo Mitsui Trust Group Inc. cut its stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 3.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,102,845 shares of the company's stock after selling 153,226 shares during the period. AbbVie accounts for 0.6% of Sumitomo Mitsui Trust Group Inc.'s holdings, making the stock its 24th largest position. Sumitomo Mitsui Trust Group Inc. owned about 0.23% of AbbVie worth $937,459,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently bought and sold shares of ABBV. Evolution Wealth Management Inc. bought a new position in AbbVie in the second quarter valued at approximately $26,000. Chelsea Counsel Co. bought a new position in AbbVie in the third quarter valued at approximately $26,000. Westend Capital Management LLC bought a new position in AbbVie in the fourth quarter valued at approximately $29,000. Texas Capital Bancshares Inc TX bought a new position in AbbVie in the third quarter valued at approximately $31,000. Finally, Caitlin John LLC bought a new position in AbbVie in the third quarter valued at approximately $33,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Stock Performance

Shares of NYSE:ABBV opened at $208.22 on Friday. The firm has a market cap of $368.16 billion, a PE ratio of 88.23, a price-to-earnings-growth ratio of 0.75 and a beta of 0.38. The firm's fifty day moving average is $220.35 and its 200-day moving average is $224.01. AbbVie Inc. has a 52 week low of $168.54 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV - Get Free Report) last released its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The business had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. During the same quarter in the previous year, the business earned $2.16 earnings per share. AbbVie's revenue for the quarter was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Sell-side analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 annualized dividend and a dividend yield of 3.3%. AbbVie's payout ratio is presently 293.22%.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. William Blair reaffirmed an "outperform" rating on shares of AbbVie in a research note on Monday, March 9th. Evercore decreased their target price on shares of AbbVie from $232.00 to $228.00 and set an "outperform" rating on the stock in a research note on Wednesday, February 4th. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $223.00 target price on shares of AbbVie in a research note on Wednesday, January 28th. BMO Capital Markets reaffirmed an "outperform" rating on shares of AbbVie in a research note on Monday, March 9th. Finally, Weiss Ratings reaffirmed a "hold (c)" rating on shares of AbbVie in a research note on Wednesday, January 21st. Two analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, AbbVie currently has an average rating of "Moderate Buy" and an average price target of $253.00.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Guggenheim raised its price target on ABBV to $249 and reiterated a Buy, signaling upside from analysts who still favor the name. Guggenheim Reiterates Buy Rating on Abbvie (ABBV)
• Positive Sentiment: Short interest fell ~19.9% in March (to ~20.1M shares), reducing short-pressure and the risk of further downside driven by short covering dynamics; days-to-cover near 2.5.
• Positive Sentiment: Analysts and features continue to highlight AbbVie's successful product transition: Skyrizi and Rinvoq are driving strong immunology growth that offsets Humira erosion — supportive for medium-term revenue and dividend durability. Battle of Big Pharma: Is AbbVie Stock Pulling Ahead of Pfizer?
• Neutral Sentiment: AbbVie has launched legal action challenging the federal 340B patient definition — this could protect pricing/discount exposure if successful but outcome and timing are uncertain. AbbVie challenges 'outdated' 340B drug discount program guidance in new lawsuit
• Neutral Sentiment: Dividend-focused coverage continues to list ABBV among reliable dividend names (Dividend Aristocrat), reinforcing long-term income investor interest but not an immediate price catalyst. 3 Dividend Aristocrats Whose Yields Can Help Combat Inflation
• Negative Sentiment: AbbVie lowered its Q1 and FY 2026 EPS guidance (Q1: 2.560–2.600 vs. consensus ~3.01; FY: 13.960–14.160 vs. consensus ~14.56), which is the primary near-term negative catalyst—investors often sell when guidance trails consensus.
• Negative Sentiment: Cantor Fitzgerald trimmed its target to $240 and warned that the upcoming Q1 season may not materially re‑energize sentiment, reinforcing caution after AbbVie's guidance revision. Cantor Fitzgerald Lowers AbbVie (ABBV) Target, Sees Weak Pharma Catalyst Ahead
• Negative Sentiment: RBC said first-quarter results are likely to land inside AbbVie's guidance and may not lift investor sentiment — a signal that the report could be bland relative to expectations. AbbVie First-Quarter Earnings Unlikely to Lift Sentiment, RBC Says
• Negative Sentiment: Broader health-care sector weakness late Friday weighed on ABBV alongside idiosyncratic negatives, amplifying downward pressure. Sector Update: Health Care Stocks Fall Late Afternoon

Insider Activity

In other news, EVP Perry C. Siatis sold 22,381 shares of the business's stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the sale, the executive vice president directly owned 38,137 shares of the company's stock, valued at $8,771,510. The trade was a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP David Ryan Purdue sold 5,230 shares of the company's stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the sale, the senior vice president directly owned 2,654 shares of the company's stock, valued at $619,868.24. The trade was a 66.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.06% of the company's stock.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.